Diltiazem Hydrochloride (Prolonged Release)Third Party Manufacturing in India

Diltiazem Hydrochloride works by selectively inhibiting the influx of calcium ions through voltage-gated L-type calcium channels in cardiac muscle and vascular smooth muscle cells. By blocking these channels, diltiazem reduces intracellular calcium availability, which decreases the contractile force of the myocardium and dilates coronary and peripheral arteries.

In the heart, diltiazem slows atrioventricular nodal conduction and prolongs the refractory period, making it effective for controlling ventricular rate in atrial fibrillation and atrial flutter. Its negative chronotropic effect reduces heart rate, while its negative inotropic effect decreases myocardial oxygen demand. On the vascular side, diltiazem relaxes arterial smooth muscle, leading to reduced peripheral vascular resistance and lower blood pressure. Unlike dihydropyridine calcium channel blockers such as nifedipine, diltiazem has a balanced effect on cardiac and vascular tissues with less reflex tachycardia.

The prolonged release formulation provides sustained drug release over 12 to 24 hours, maintaining therapeutic plasma concentrations throughout the dosing interval. This allows once or twice-daily administration, improving patient adherence in chronic conditions such as hypertension and stable angina where consistent blood pressure control is essential for long-term cardiovascular outcomes.

Diltiazem Hydrochloride is a benzothiazepine calcium channel blocker used extensively in the management of cardiovascular disorders. The prolonged release formulation enables once-daily dosing for chronic conditions.

Therapeutic Uses

• Hypertension: Reduces blood pressure through peripheral vasodilation and is effective as monotherapy or in combination with ACE inhibitors, diuretics, or beta blockers.
• Stable Angina Pectoris: Improves exercise tolerance and reduces anginal episodes by decreasing myocardial oxygen demand and increasing coronary blood flow.
• Variant (Prinzmetal's) Angina: First-line therapy for coronary artery spasm due to its direct vasodilatory effect on coronary arteries.
• Atrial Fibrillation and Atrial Flutter: Controls ventricular rate by slowing AV nodal conduction, particularly useful in patients with concomitant hypertension or coronary artery disease.
• Supraventricular Tachycardia: Used intravenously for acute termination and orally for long-term prophylaxis of recurrent episodes.

Why Manufacturers Choose Diltiazem Hydrochloride

Diltiazem Hydrochloride occupies a significant share of the Indian cardiovascular market, driven by the rising prevalence of hypertension and ischemic heart disease. The prolonged release formulation is particularly valued by clinicians for its smooth pharmacokinetic profile and better tolerability compared with immediate-release formulations. Indian manufacturers with WHO-GMP certified facilities produce diltiazem prolonged release tablets for both domestic PCD franchise networks and export to regulated markets in the Middle East, Africa, and Southeast Asia. The established supply chain for the active pharmaceutical ingredient and well-documented formulation science make diltiazem an efficient molecule for third party manufacturing, with consistent demand across hospital and retail channels. This makes Diltiazem Hydrochloride prolonged release a high-volume opportunity for contract manufacturers serving the cardiac segment.